Clinical Trials Browser

Phase 2/3 × Unknown × aumolertinib × Clear all

NCT05994339 2023-08-29

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Phase 2/3 Unknown

Lung Neoplasms